Parkman Healthcare Partners LLC Purchases 24,839 Shares of NewAmsterdam Pharma Company N.V. $NAMS

Key Points

• Parkman Healthcare Partners LLC increased its stake in NewAmsterdam Pharma by 32.6% in the first quarter, acquiring an additional 24,839 shares, bringing its total holdings to 100,955 shares valued at approximately $2.07 million.
• The company reported a quarterly loss with an EPS of ($0.15), which exceeded analyst expectations of ($0.52) per share, alongside a revenue of $19.15 million compared to the anticipated $1.44 million.
• NewAmsterdam Pharma has received favorable ratings from multiple analysts, including a target price increase from Royal Bank of Canada from $38.00 to $39.00, and has a consensus rating of "Moderate Buy" with a price target of $41.55.

Parkman Healthcare Partners LLC lifted its position in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 32.6% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 100,955 shares of the company's stock after buying an additional 24,839 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.09% of NewAmsterdam Pharma worth $2,067,000 as of its most recent filing with the SEC.

Several other large investors have also made changes to their positions in NAMS. Frazier Life Sciences Management L.P. grew its stake in shares of NewAmsterdam Pharma by 23.8% in the 4th quarter. Frazier Life Sciences Management L.P. now owns 15,916,418 shares of the company's stock valued at $409,052,000 after buying an additional 3,061,224 shares in the last quarter. Wellington Management Group LLP boosted its position in NewAmsterdam Pharma by 2,410.4% during the fourth quarter. Wellington Management Group LLP now owns 2,315,123 shares of the company's stock worth $59,499,000 after purchasing an additional 2,222,900 shares during the period. RA Capital Management L.P. boosted its position in NewAmsterdam Pharma by 14.6% during the first quarter. RA Capital Management L.P. now owns 10,138,938 shares of the company's stock worth $207,544,000 after purchasing an additional 1,293,938 shares during the period. Woodline Partners LP grew its stake in shares of NewAmsterdam Pharma by 108.7% in the fourth quarter. Woodline Partners LP now owns 2,430,782 shares of the company's stock worth $62,471,000 after acquiring an additional 1,266,105 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in NewAmsterdam Pharma by 85.8% during the first quarter. Adage Capital Partners GP L.L.C. now owns 1,950,650 shares of the company's stock worth $39,930,000 after acquiring an additional 900,650 shares during the period. Institutional investors own 89.89% of the company's stock.

NewAmsterdam Pharma Stock Performance

Shares of NAMS stock opened at $27.00 on Friday. The company has a market capitalization of $3.04 billion, a P/E ratio of -16.67 and a beta of -0.01. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $27.29. The company's 50 day moving average price is $22.98 and its two-hundred day moving average price is $20.55.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.37. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative return on equity of 27.27%. The business had revenue of $19.15 million for the quarter, compared to analysts' expectations of $1.44 million. Analysts forecast that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current year.

Insider Transactions at NewAmsterdam Pharma

In other NewAmsterdam Pharma news, COO Douglas F. Kling sold 100,000 shares of the company's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $19.29, for a total transaction of $1,929,000.00. Following the completion of the transaction, the chief operating officer owned 44,000 shares of the company's stock, valued at $848,760. This represents a 69.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Johannes Jacob Piete Kastelein sold 50,000 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $24.29, for a total value of $1,214,500.00. Following the transaction, the insider directly owned 119,302 shares of the company's stock, valued at approximately $2,897,845.58. This trade represents a 29.53% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders bought 12,835 shares of company stock worth $248,134 and sold 274,954 shares worth $5,899,406. 20.84% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

NAMS has been the subject of a number of recent research reports. Royal Bank Of Canada upped their target price on NewAmsterdam Pharma from $38.00 to $39.00 and gave the company an "outperform" rating in a research note on Thursday, August 7th. Cantor Fitzgerald started coverage on NewAmsterdam Pharma in a research note on Wednesday, June 4th. They issued an "overweight" rating and a $42.00 target price for the company. The Goldman Sachs Group started coverage on NewAmsterdam Pharma in a research note on Thursday, July 17th. They issued a "neutral" rating and a $27.00 target price for the company. Stifel Nicolaus started coverage on NewAmsterdam Pharma in a research note on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Finally, Needham & Company LLC restated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research note on Thursday, June 12th. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $41.55.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.